Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HBB | P68871 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26378122 | 0.81 | GRIN1 (0.40) | POLBALDH1A1 | |
| SCHEMBL26187481 | 0.79 | LPAR1 (0.37) | TSHRPOLB | |
| SCHEMBL5755544 | 0.70 | OPRM1 (0.43) | TRPA1GAASMN1; SMN2OPRL1 | |
| SCHEMBL11704572 | 0.69 | SIGMAR1 (0.39) | TRPA1ALOX15TSHRMAPK1 | |
| SCHEMBL26187485 | 0.68 | TSHR (0.39) | GAAMAPTTSHRKDM4EALDH1A1 | |
| SCHEMBL21436223 | 0.67 | HDAC4 (0.40) | SMN1; SMN2OPRL1 | |
| SCHEMBL24969365 | 0.67 | HDAC4 (0.40) | SMN1; SMN2OPRL1 | |
| SCHEMBL20934329 | 0.66 | SLC6A4 (0.47) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL21436202 | 0.66 | HDAC4 (0.39) | SMN1; SMN2OPRL1 | |
| SCHEMBL1381231 | 0.65 | CYP19A1 (0.36) | POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022767-A1 | SALTS OF (2R, 6R)-HYDROXYNORKETAMINE, THEIR CRYSTAL FORMS, AND METHODS OF MAKING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022767-A1 | SALTS OF (2R, 6R)-HYDROXYNORKETAMINE, THEIR CRYSTAL FORMS, AND METHODS OF MAKING THE SAME | KHK, GCK, HK1 | PDK2 43/4885PDK4 59/4885TRPA1 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.